1-<<(1,1-dimethylethyl)amino>methyl>cyclohexanol | 65055-38-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-<<(1,1-dimethylethyl)amino>methyl>cyclohexanol
• 英文别名: 1-((tert-Butylamino)methyl)cyclohexan-1-ol；1-[(tert-butylamino)methyl]cyclohexan-1-ol
• CAS: 65055-38-1
• 化学式: C₁₁H₂₃NO
• 分子量: 185.31
• InChiKey: LDPUSERNACUJIG-UHFFFAOYSA-N

物化性质

• 沸点：
  95 °C(Press: 0.75 Torr)
• 密度：
  0.936±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-((1-((2,2-dimethylpropanoyl)oxy)cyclohexyl)-methylidene)-1,1-dimethylethanamine 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 反应 3.0h， 生成 1-<<(1,1-dimethylethyl)amino>methyl>cyclohexanol
  参考文献：
  名称：

  Preparation of vicinal N-alkylamino alcohols via acylation-rearrangement of nitrones followed by hydride reduction

  摘要：

  DOI：

  10.1021/jo00359a002

文献信息

• .alpha.-Oxygenation of aldehydes and cyclic ketones by acylation-rearrangement of nitrones
  作者：Clark H. Cummins、Robert M. Coates

  DOI：10.1021/jo00160a027

  日期：1983.6
• De Kimpe,N. et al., Recueil des Travaux Chimiques des Pays-Bas, 1977, vol. 96, p. 242 - 246
  作者：De Kimpe,N. et al.

  DOI：——

  日期：——
• AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS
  申请人：Epizyme, Inc.

  公开号：US20170355712A1

  公开（公告）日：2017-12-14

  The present disclosure relates to amine-substituted aryl or heteroaryl compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibition of a methyltransferase enzyme selected from EHMT1 and EHMT2, by administering an amine-substituted aryl or heteroaryl compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
• COMBINATION THERAPIES WITH EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200054635A1

  公开（公告）日：2020-02-20

  The present disclosure relates to a method of preventing or treating a cancer via administering an EHMT2 inhibitor or a combination comprising an EHMT2 inhibitor compound and one or more additional therapeutic agent disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds or combinations for research or other non-therapeutic purposes.
• METHODS OF USING EHMT2 INHIBITORS
  申请人：Epizyme, Inc.

  公开号：US20200113901A1

  公开（公告）日：2020-04-16

  The present disclosure relates to a method of preventing or treating an imprinting disorder via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.